Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre dEtudes pour lIndustrie Pharmaceutique
Original Assignee
Centre dEtudes pour lIndustrie Pharmaceutique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7303503Aexternal-prioritypatent/FR2215948B1/fr
Application filed by Centre dEtudes pour lIndustrie PharmaceutiquefiledCriticalCentre dEtudes pour lIndustrie Pharmaceutique
Priority to CA000293187ApriorityCriticalpatent/CA1042438A/fr
Application grantedgrantedCritical
Publication of CA1042438ApublicationCriticalpatent/CA1042438A/fr
Novel basic-substituted 5-halo-thienoisothiazol-3(2H)-one 1,1-dioxides, a process for the preparation thereof, and pharmaceutical preparations containing these compounds
3-((4-methyl-1-piperazinyl carbonyl)oxy)-2-(2-quinolyl)-1-isoindoline derivatives,process for their preparation and pharmaceutical compositions containing the same